AB-Biotics granted European patent for AB-Life

AB-Biotics granted European patent for AB-Life

Probiotic is already licensed in some European, American and Asian markets and is expected to launched in new markets in 2014.

The Spanish biotech company AB-Biotics announced that the European Patent Office (EPO) has granted a patent that protects the composition of its healthy cholesterol-supporting probiotic AB-Life.

Filed on September 28, 2010, the patent (EP2485743) protects compositions comprising the probiotic strains of Lactobacillus plantarum CECT 757, CECT 7528 and CECT 7529. These new strains have good probiotic features and are useful for managing cardiovascular health. The compositions comprising AB-Life strains can be pharmaceutical, veterinary and edible compositions. The patent also protects the administration of AB-Life with other products such as statins, thereby allowing reduction of the dose of these widely used drugs.

"This patent is a major milestone that allows us to protect AB-Life in one of the most important markets for AB-Biotics: Europe", said Sergi Audivert and Miquel Angel Bonachera, cofounders and co-CEOs of AB-Biotics.

AB-Biotics has already signed license agreements with different pharma companies to distribute AB-Life in Southeast Europe (through Inspharma), Germany (HLH Biopharma) and Spain and Portugal (Lacer), and also in South Korea (HanAll BioPharma), Mexico (Armstrong Laboratories), Brazil (Biolab) and Venezuela (Leti). AB-Biotics expects to license the product in new European markets, like United Kingdom or Italy, in 2014.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.